Infectious Diseases News and Research

RSS

WRAIR to test Kane Biotech's DispersinB biofilm technology against pathogens in combat trauma wounds

Kane Biotech Inc. (TSX VENTURE:KNE), a biotechnology company engaged in the development of products that prevent and remove microbial biofilms is pleased to announce that the Company has entered into a Cooperative Research and Development Agreement for Material Transfer (CRADA-MT) with the Walter Reed Army Institute of Research (WRAIR) in Silver Springs, Maryland.

9 Sep 2009

MRSA awareness event to be held at Loyola University Chicago

MRSA Survivors Network, the Chicago-based nonprofit and official organization for World MRSA Day, along with fellow MRSA activists will lift the veil of secrecy surrounding MRSA. The history making inaugural kick-off event will be held at Loyola University Chicago on October 1st. The 2009 theme is "You Can Not Change What You Do Not Acknowledge."

9 Sep 2009

International summit on the H1N1 influenza pandemic and critical business preparedness

The Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota is convening an international summit on the H1N1 influenza pandemic and critical business preparedness.

9 Sep 2009

Ceragenix awarded $2.87M NIH grant to develop a drug for treating Clostrdium difficile and Shigella

Ceragenix Pharmaceuticals, Inc. (“Ceragenix”) (OTCBB:CGXP), a medical device company focused on infectious disease and dermatology, today announced that the National Institutes of Health (“NIH”) has awarded a $2.87 million grant to fund the pre clinical development of a Ceragenin™based oral drug to treat two common and potentially deadly gastrointestinal infections: Clostrdium difficile and Shigella.

9 Sep 2009

International Institute of Biomedical Sciences and Technology established for a global research initiative

Upstate Medical University in Syracuse, New York, the Technion-Israel Institute of Technology in Haifa, Israel, and National Cheng Kung University in Tainan City, Taiwan, have announced the creation of the International Institute of Biomedical Sciences and Technology that will facilitate the collaboration of research across three continents and accelerate the development of novel bioengineering, diagnostic and biomedical products for the treatment and cure of disease, officials said today.

9 Sep 2009

ORT remains underutilized in U.S. prison systems

Almost a quarter of a million individuals addicted to heroin are incarcerated in the United States each year. However, many prison systems across the country still do not offer medical treatment for heroin and opiate addiction, despite the demonstrated social, medical and economic benefits of opiate replacement therapy (ORT).

9 Sep 2009

Bioluminescence imaging demystifies causes of infectious diseases

By attaching light-emitting genes to infectious bacteria in an experimental system, researchers at University College, Cork, Ireland, have been able to track where in the body the bacteria go - giving an insight into the path of the infection process leading to the development of more targeted treatments.

9 Sep 2009

Consortium awarded $3.75M to set up an AIDS research center in Chicago

The National Institutes of Health (NIH) has awarded a consortium of Chicago-based institutions, led by Rush University Medical Center, a five-year, $3.75-million grant to establish a Developmental Center for AIDS Research, creating a comprehensive research infrastructure to spur basic science, clinical studies and translational research in the prevention, detection and treatment of HIV infection and AIDS.

9 Sep 2009

NIH awards Vaxart $2.8M grant to develop an orally-delivered H5N1 Avian influenza vaccine

Vaxart, Inc., a San Francisco biotechnology company developing oral-delivery vaccines, has been awarded a $2.8 million phase II Small Business Innovation Research grant from the National Institute of Allergy and Infectious Disease (National Institutes of Health) to support development of its first product, an orally-delivered vaccine for H5N1 Avian influenza.

9 Sep 2009

Biomagnetics Diagnostics deploys IOBS testing technology

Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis, and malaria detection, today announced its entry into the Integrated Optical Biosensor System (IOBS) market. IOBS are a relatively new classification of pathogen detection equipment which use advanced fiber optic-based technology to detect a wide variety of human and animal pathogens.

9 Sep 2009

Harmless shard from childhood virus shell may halt biological process

A harmless shard from the shell of a common childhood virus may halt a biological process that kills a significant percentage of battlefield casualties, heart attack victims and oxygen-deprived newborns, according to research presented Sunday, September 6, 2009, at the 12th European meeting on complement in human disease in Budapest, Hungary.

7 Sep 2009

Recent releases: PEPFAR in Zimbabwe; dengue in Thailand; blogs on improving U.S. foreign aid; examining allocations of health aid

The U.S. plans to support efforts to develop a sustainable health system in Zimbabwe and increase its capacity to treat people, Eric Goosby, U.S. global AIDS Coordinator for PEPFAR, said on Wednesday after a visit to the country with USAID and CDC officials, according to a press release from the U.S. Embassy in Harare, Zimbabwe. Goosby said he is "optimistic" that the Zimbabwe PEPFAR team's experience will be used "to develop a response that fits the existing health infrastructure, supports it and reinforces it in a way that creates a durable and lasting response" (9/2).

5 Sep 2009

New protein fragments identified for anthrax vaccine development

Researchers at Albert Einstein College of Medicine of Yeshiva University have identified two small protein fragments that could be developed into an anthrax vaccine that may cause fewer side effects than the current vaccine.

4 Sep 2009

Novel SLE Responder Index as the primary endpoint in two Phase 3 clinical trials

Human Genome Sciences, Inc. today announced publication by the journal Arthritis Care & Research of an article describing the development and use of a novel evidence-based systemic lupus erythematosus (SLE) Responder Index selected as the primary endpoint of two pivotal Phase 3 clinical trials of BENLYSTA (belimumab) in serologically active patients with SLE.

4 Sep 2009

rPA anthrax vaccine and its Valortim anthrax anti-toxin program data presented

PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, announced today that data from the Company's third generation recombinant protective antigen (rPA) anthrax vaccine program and its Valortim((R)) anthrax anti-toxin program were presented at the Bacillus - ACT 2009 meeting, August 30 - September 3, 2009, organized by the American Society for Microbiology.

4 Sep 2009

Dr Lluis Quintana-Murci from the Institut Pasteur in France honoured with the Debiopharm Life Sciences Award

Debiopharm Group, SA (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today presented the 'Debiopharm Life Sciences Award' to Dr Lluis Quintana-Murci from the Institut Pasteur in France, for his outstanding innovative research in the emerging field of evolutionary genetics of infection.

4 Sep 2009

New H1N1 Influenza detection test used to diagnose Australia's first swine flu victim

When the first cases of H1N1 Influenza (swine flu) were reported in Mexico in April, UQ researchers got to work developing a test to diagnose the virus.

4 Sep 2009

Touch of MIDAS to prepare the world for contagious outbreaks

To help the nation-and the world-understand and prepare for contagious outbreaks, the National Institutes of Health's Models of Infectious Disease Agent Study (MIDAS) adds new research expertise to increase its capacity to simulate disease spread, evaluate different intervention strategies and help inform public health officials and policymakers.

4 Sep 2009

Clinical trial of Novartis MF59 swine-flu vaccine elicits a strong immune response

Results from the first swine-flu vaccine trials taking place in Leicester reveal a strong immune response after just one dose.

4 Sep 2009

New center to study mathematical modeling of drug resistance and internention to be established at HSPH

A new center that will focus on mathematical modeling of drug resistance, seasonal infectious diseases, and intervention allocation will be established at the Harvard School of Public Health (HSPH).

4 Sep 2009

Infectious Diseases News and Research

WRAIR to test Kane Biotech's DispersinB biofilm technology against pathogens in combat trauma wounds

MRSA awareness event to be held at Loyola University Chicago

International summit on the H1N1 influenza pandemic and critical business preparedness

Ceragenix awarded $2.87M NIH grant to develop a drug for treating Clostrdium difficile and Shigella

International Institute of Biomedical Sciences and Technology established for a global research initiative

ORT remains underutilized in U.S. prison systems

Bioluminescence imaging demystifies causes of infectious diseases

Consortium awarded $3.75M to set up an AIDS research center in Chicago

NIH awards Vaxart $2.8M grant to develop an orally-delivered H5N1 Avian influenza vaccine

Biomagnetics Diagnostics deploys IOBS testing technology

Harmless shard from childhood virus shell may halt biological process

Recent releases: PEPFAR in Zimbabwe; dengue in Thailand; blogs on improving U.S. foreign aid; examining allocations of health aid

New protein fragments identified for anthrax vaccine development

Novel SLE Responder Index as the primary endpoint in two Phase 3 clinical trials

rPA anthrax vaccine and its Valortim anthrax anti-toxin program data presented

Dr Lluis Quintana-Murci from the Institut Pasteur in France honoured with the Debiopharm Life Sciences Award

New H1N1 Influenza detection test used to diagnose Australia's first swine flu victim

Touch of MIDAS to prepare the world for contagious outbreaks

Clinical trial of Novartis MF59 swine-flu vaccine elicits a strong immune response

New center to study mathematical modeling of drug resistance and internention to be established at HSPH

Industry Focus: Infectious Diseases eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News